Detalhe da pesquisa
1.
NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
J Hepatol
; 80(2): 209-219, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38061448
2.
NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
J Hepatol
; 79(3): 758-767, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224923
3.
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
JHEP Rep
; 6(4): 101011, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38463540
4.
NIS2+™, an effective blood-based test for the diagnosis of at-risk nonalcoholic steatohepatitis in adults 65 years and older.
Hepatol Commun
; 7(9)2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556372
5.
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Lancet Gastroenterol Hepatol
; 5(11): 970-985, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763196